ACE and stroke disorder: The HOPE study showed a 22% reduction in cardiovascular events (MI, stroke, cardiac arrest, revascualrization, heart failure, death) in metabolic syndrome patients and without hypertension treated with an ACE inhibitor, ramipril versus metabolic syndrome patients without hypertension not treated with an ACE inhibitor [130].